RxDoctor Payments Data

Sergey Turchin, MD

Internal Medicine · Jacksonville, FLNPI 1033177878

Payments from drug & device makers

$459in general payments, 2019–2025

Across 25 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$102
  • GSK$78
  • Novo Nordisk$54
  • Amgen$53
  • AbbVie$31
  • Merck$24
  • plus $117 from 7 others

What the payments were for

  • Food & beverage$459100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$459 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$127,908
Medicare patients
652
Services billed
1,204

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$104,502
EliquisApixaban55$54,731
TrulicityDulaglutide33$34,323
JardianceEmpagliflozin18$24,823
MounjaroTirzepatide17$22,001
JanuviaSitagliptin Phosphate23$17,033
Praluent PenAlirocumab21$13,482
LinzessLinaclotide22$12,570
Repatha SureclickEvolocumab17$11,515
FarxigaDapagliflozin Propanediol18$10,428
XareltoRivaroxaban14$10,051
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$9,521
SynthroidLevothyroxine Sodium113$8,339
Atorvastatin Calcium704$7,126
Tresiba Flextouch U-100Insulin Degludec12$5,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$54$104,502102 claims
Lilly USA, LLCTrulicity, Mounjaro$102$56,32550 claims
Boehringer IngelheimJardiance$18$24,82318 claims
AbbVieLinzess, Synthroid$31$20,908135 claims
MerckJanuvia$24$17,03323 claims
AstraZenecaFarxiga$16$10,42818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →